Biotech · Private company
Atox Bio Ltd
Track this companyFree. Adds Atox Bio Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials40 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- AB103 0.5 mg/kgPhase 3 · Necrotizing Soft Tissue InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- NaCl 0.9%Phase 3 · Necrotizing Soft Tissue InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- Reltecimod 0.5 mg/kgPhase 3 · Acute Kidney InjuryClinicalTrials.gov · fetched Nov 12, 2026
- AB103Phase 2 · Necrotizing Soft Tissue InfectionsClinicalTrials.gov · fetched Nov 12, 2026
- AB103Phase 1 · Healthy Volunteer Safety StudyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials4
- Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney InjuryPHASE3 · TERMINATED · started May 24, 2018ClinicalTrials.gov NCT03403751 · fetched Nov 12, 2026
- Phase III Efficacy and Safety Study of AB103 in the Treatment of Patients With Necrotizing Soft Tissue InfectionsPHASE3 · COMPLETED · started Dec 1, 2015ClinicalTrials.gov NCT02469857 · fetched Nov 12, 2026
- Evaluation of Safety, PK and Immunomodulatory Effects of AB103 in Necrotizing Soft Tissue Infections PatientsPHASE2 · COMPLETED · started Dec 1, 2011ClinicalTrials.gov NCT01417780 · fetched Nov 12, 2026
- AB103 Peptide Antagonist in Healthy VolunteersPHASE1 · COMPLETED · started Sep 1, 2010ClinicalTrials.gov NCT01166984 · fetched Nov 12, 2026